These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6123801)

  • 1. Pertussis vaccine.
    Robinson A; Ashworth LA; Irons L
    Lancet; 1982 Jul; 2(8289):108. PubMed ID: 6123801
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant microbial ADP-ribosylating toxins of Bordetella pertussis, Vibrio cholerae, and enterotoxigenic Escherichia coli: structure, function, and toxoid vaccine development.
    Burnette WN; Cieplak W; Kaslow HR; Rappuoli R; Tuomanen EI
    Bioprocess Technol; 1994; 19():185-203. PubMed ID: 7764758
    [No Abstract]   [Full Text] [Related]  

  • 3. Bordetella pertussis toxins.
    Wardlaw AC; Parton R
    Pharmacol Ther; 1982; 19(1):1-53. PubMed ID: 6304790
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intracellular structural arrangement of pertussis toxins (factors) and suggestions on production of safe and effective vaccines].
    Kuwajima Y
    Kansenshogaku Zasshi; 1978 Feb; 52(2):56-9. PubMed ID: 213507
    [No Abstract]   [Full Text] [Related]  

  • 5. [Toxic factors of Bordetella pertussis, with special reference to leukocytosis-promoting factor, histamine-sensitizing factor and hemagglutinins (author's transl)].
    Sato Y
    Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():164-83. PubMed ID: 194282
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental relation between histamine-sensitizing factor and the protective antigen of Bordetella pertussis].
    Jiménez Paredes J; Ruiz Puente J; González Pacheco M
    Salud Publica Mex; 1981; 23(6):621-9. PubMed ID: 6278660
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
    Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N
    Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogenetic significance of Bordetella pertussis toxin].
    Finger H
    Immun Infekt; 1985 Apr; 13(2):47-9. PubMed ID: 2860059
    [No Abstract]   [Full Text] [Related]  

  • 10. Further contributions to an improved pertussis vaccine: I. Molecular mechanisms of pertussis toxin.
    Aktories K; Jakobs KH; Robbel L
    Behring Inst Mitt; 1984 Nov; (76):106-9. PubMed ID: 6098260
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular aspects of Bordetella pertussis pathogenesis.
    Locht C
    Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial growth and virulence factors production by different Bordetella pertussis strains.
    Letowska I; Chodorowska M; Kaczurba E; Kuklińska D; Tyski S
    Acta Microbiol Pol; 1997; 46(1):45-55. PubMed ID: 9271847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pertussis component vaccine in Japan.
    Sato Y; Kimura M; Fukumi H
    Lancet; 1984 Jan; 1(8369):122-6. PubMed ID: 6140441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pertactin in pertussis vaccines: the jury is still out.
    Desauziers E; Danve B; Decker MD; Veitch K
    J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children.
    Ashworth LA; Robinson A; Irons LI; Morgan CP; Isaacs D
    Lancet; 1983 Oct; 2(8355):878-81. PubMed ID: 6137697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acellular anti-pertussis vaccine].
    Bégué P; Grimpel E; Baron S
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):859-65. PubMed ID: 1819434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid.
    Robbins JB; Schneerson R; Trollfors B; Taranger J; Lagergård T
    Dev Biol Stand; 1998; 95():155-8. PubMed ID: 9855426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of Bordetella strains used in the production of anti-pertussis vaccine in stationary culture].
    Castillejos Carmona R; González Pacheco M
    Salud Publica Mex; 1981; 23(6):549-53. PubMed ID: 6278653
    [No Abstract]   [Full Text] [Related]  

  • 19. [Properties of an acellular preparation of Bordetella pertussis and its analysis after centrifugation in saccharose gradient].
    Letowska I; Kaczurba E; Schiller B
    Med Dosw Mikrobiol; 1993; 45(3):289-94. PubMed ID: 8189799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine.
    Novotny P; Chubb AP; Cownley K; Charles IG
    J Infect Dis; 1991 Jul; 164(1):114-22. PubMed ID: 2056199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.